DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108. A total of 113 filers reported holding DICERNA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $10,354,000 | -55.2% | 513,612 | -17.0% | 0.00% | -50.0% |
Q2 2021 | $23,090,000 | +46.0% | 618,712 | 0.0% | 0.00% | +100.0% |
Q1 2021 | $15,820,000 | -0.6% | 618,712 | -14.4% | 0.00% | 0.0% |
Q4 2020 | $15,917,000 | +22.5% | 722,512 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $12,998,000 | -29.2% | 722,512 | 0.0% | 0.00% | -50.0% |
Q2 2020 | $18,352,000 | +38.3% | 722,512 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $13,273,000 | -16.6% | 722,512 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $15,917,000 | +65.9% | 722,512 | +8.2% | 0.00% | +100.0% |
Q3 2019 | $9,592,000 | -8.8% | 667,948 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $10,520,000 | -18.8% | 667,948 | -24.5% | 0.00% | -50.0% |
Q1 2019 | $12,962,000 | +9.9% | 884,748 | -19.8% | 0.00% | 0.0% |
Q4 2018 | $11,791,000 | -30.5% | 1,102,948 | -0.8% | 0.00% | 0.0% |
Q3 2018 | $16,961,000 | -4.1% | 1,111,462 | -23.0% | 0.00% | 0.0% |
Q2 2018 | $17,688,000 | +8.3% | 1,443,911 | -15.5% | 0.00% | 0.0% |
Q1 2018 | $16,329,000 | +5.9% | 1,708,011 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $15,423,000 | +82.3% | 1,708,011 | +16.1% | 0.00% | +100.0% |
Q3 2017 | $8,459,000 | +13.6% | 1,471,111 | -37.4% | 0.00% | 0.0% |
Q2 2017 | $7,449,000 | -20.7% | 2,349,710 | -14.9% | 0.00% | 0.0% |
Q1 2017 | $9,391,000 | +18.0% | 2,762,011 | -0.0% | 0.00% | 0.0% |
Q4 2016 | $7,956,000 | -52.6% | 2,762,611 | -3.3% | 0.00% | -50.0% |
Q3 2016 | $16,799,000 | +80.1% | 2,856,911 | -8.1% | 0.00% | +100.0% |
Q2 2016 | $9,327,000 | -43.8% | 3,108,916 | +0.4% | 0.00% | -50.0% |
Q1 2016 | $16,601,000 | -54.7% | 3,097,197 | +0.3% | 0.00% | -60.0% |
Q4 2015 | $36,666,000 | +44.6% | 3,088,967 | +0.0% | 0.01% | +25.0% |
Q3 2015 | $25,360,000 | -41.1% | 3,088,916 | +0.1% | 0.00% | -33.3% |
Q2 2015 | $43,057,000 | -32.9% | 3,086,516 | +15.5% | 0.01% | -25.0% |
Q1 2015 | $64,208,000 | +46.2% | 2,671,994 | +0.2% | 0.01% | +33.3% |
Q4 2014 | $43,909,000 | +29.4% | 2,665,993 | +0.0% | 0.01% | +20.0% |
Q3 2014 | $33,929,000 | -43.6% | 2,665,315 | +0.0% | 0.01% | -37.5% |
Q2 2014 | $60,137,000 | -18.2% | 2,664,457 | +2.4% | 0.01% | -20.0% |
Q1 2014 | $73,517,000 | – | 2,602,403 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 1,355,392 | $29,859,000 | 6.21% |
Bain Capital Life Sciences Investors, LLC | 3,080,237 | $67,858,000 | 4.26% |
DAFNA Capital Management LLC | 587,756 | $12,948,000 | 3.85% |
SILVERARC CAPITAL MANAGEMENT, LLC | 227,388 | $5,009,000 | 2.91% |
RTW INVESTMENTS, LP | 7,253,857 | $159,802,000 | 2.68% |
Parkman Healthcare Partners LLC | 331,513 | $7,303,000 | 1.87% |
Evolutionary Tree Capital Management, LLC | 60,864 | $1,341,000 | 1.02% |
Eagle Health Investments LP | 69,000 | $1,520,000 | 0.97% |
Woodline Partners LP | 1,358,796 | $29,934,000 | 0.79% |
Affinity Asset Advisors, LLC | 40,000 | $881,000 | 0.47% |